Joseph B. Cantey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joseph B. Cantey has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Pablo J. Sanchez
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX
3 shared publications Pablo J. Sánchez
Department of Pediatrics, Center for Perinatal Research, Nationwide Children's Hospital, The Ohio State University, Columbus, OH
3 shared publications- Aaron M. Milstone
Johns Hopkins University School of Medicine
1 shared publication Alan M. Klein
Department of Pediatrics, Methodist Dallas Medical Center, Dallas, TX
1 shared publicationAvante Milton
1 shared publicationChristopher D. Doern
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA Department of Pathology, Children's Medical Center Dallas, Dallas, Texas, USA
1 shared publication
Latest Publications
- Open Access
- 1 September 2016
- Published by Elsevier in Jornal de Pediatria (Versão em Português)
- Vol. 92 (5) , 432-435
Empiric therapy with vancomycin in the neonatal intensive care unit: let's “get smart” globally!
- 1 September 2016
- Published by Elsevier in Jornal de Pediatria (Versão em Português)
- Vol. 92 (5) , 432-435
Open AccessEmpiric therapy with vancomycin in the neonatal intensive care unit: let's “get smart” globally!
- 1 July 2015
- Published by Elsevier in Early Human Development
- Vol. 91 (7) , 427-430
The etiology of lenticulostriate vasculopathy and the role of congenital infections
- 1 July 2015
- Published by Elsevier in Early Human Development
- Vol. 91 (7) , 427-430
The etiology of lenticulostriate vasculopathy and the role of congenital infections
- 1 May 2015
- Published by Elsevier in The Journal of Pediatrics
- Vol. 166 (5) , 1308-1309
Herpes Simplex Virus DNAemia Preceding Neonatal Disease
- 1 May 2015
- Published by Elsevier in The Journal of Pediatrics
- Vol. 166 (5) , 1308-1309
Herpes Simplex Virus DNAemia Preceding Neonatal Disease
- Open Access
- 1 April 2015
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 53 (4) , 1282-1285
Lack of Clinical Utility of Urine Gram Stain for Suspected Urinary Tract Infection in Pediatric Patients
Urinary tract infection (UTI) is one of the most common infections in children. Urine culture remains the gold standard for diagnosis, but the utility of urine Gram stain relative to urinalysis (UA) is unclear. We reviewed 312 pediatric patients with suspected UTI who had urine culture, UA, and urine Gram stain performed from a single urine specimen. UA was considered positive if ≥ 10 leukocytes per oil immersion field were seen or if either nitrates or leukocyte esterase testing was positive. Urine Gram stain was considered positive if any organisms were seen. Sensitivity, specificity, and positive and negative predictive value were calculated using urine culture as the gold standard. Thirty-seven (12%) patients had a culture-proven UTI. Compared to urine Gram stain, UA had equal sensitivity (97.3% vs. 97.5%) and higher specificity (85% vs 74%). Empiric therapy was prescribed before the Gram stain result was known in 40 (49%) patients and after in 42 (51%) patients. The antibiotics chosen did not differ between these two groups (p=0.81), nor did they differ for patients with Gram-negative rods on urine Gram stain compared to those with Gram-positive cocci (p=0.67). From this data we conclude that UA has excellent negative predictive value that is not enhanced by urine Gram stain and antibiotic selection did not vary based on the urine Gram stain result. In conclusion, the clinical utility of urine Gram staining does not warrant the time or cost it requires.
- 1 April 2015
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 53 (4) , 1282-1285
Open AccessLack of Clinical Utility of Urine Gram Stain for Suspected Urinary Tract Infection in Pediatric Patients
Urinary tract infection (UTI) is one of the most common infections in children. Urine culture remains the gold standard for diagnosis, but the utility of urine Gram stain relative to urinalysis (UA) is unclear. We reviewed 312 pediatric patients with suspected UTI who had urine culture, UA, and urine Gram stain performed from a single urine specimen. UA was considered positive if ≥ 10 leukocytes per oil immersion field were seen or if either nitrates or leukocyte esterase testing was positive. Urine Gram stain was considered positive if any organisms were seen. Sensitivity, specificity, and positive and negative predictive value were calculated using urine culture as the gold standard. Thirty-seven (12%) patients had a culture-proven UTI. Compared to urine Gram stain, UA had equal sensitivity (97.3% vs. 97.5%) and higher specificity (85% vs 74%). Empiric therapy was prescribed before the Gram stain result was known in 40 (49%) patients and after in 42 (51%) patients. The antibiotics chosen did not differ between these two groups (p=0.81), nor did they differ for patients with Gram-negative rods on urine Gram stain compared to those with Gram-positive cocci (p=0.67). From this data we conclude that UA has excellent negative predictive value that is not enhanced by urine Gram stain and antibiotic selection did not vary based on the urine Gram stain result. In conclusion, the clinical utility of urine Gram staining does not warrant the time or cost it requires.
- 1 March 2015
- Published by Elsevier in Clinics in Perinatology
- Vol. 42 (1) , 1-16
Bloodstream Infections
- 1 March 2015
- Published by Elsevier in Clinics in Perinatology
- Vol. 42 (1) , 1-16
Bloodstream Infections
- 1 March 2015
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 34 (3) , 267-272
Prospective Surveillance of Antibiotic Use in the Neonatal Intensive Care Unit
Background: Prolonged or unnecessary antibiotic use is associated with adverse outcomes in neonates. Our objectives were to quantify all antibiotic use in a Level-III neonatal intensive care unit and to identify scenarios where their use could be reduced. Methods: Surveillance and evaluation of all antibiotic use provided to every infant admitted to a Level-III neonatal intensive care unit from 10/3/11 to 11/30/12 was performed. Types of antibiotics, reasons for their initiation, discontinuation and duration, as well as clinical, laboratory and outcome data were recorded. Antibiotic use was quantified by days of therapy (DOT) per 1000 patient-days (PD). Results: A total of 1607 infants were included. The total antibiotic use was 9165 DOT (343.2 DOT/1000 PD; 5.7 DOT/infant). Seventy-two percent of infants received 1 (43%) or more (29%) courses of antibiotics. Gentamicin (46%), ampicillin (39%) and oxacillin (8%) were the most frequently used agents. Ninety-four percent of antibiotic use (323 DOT/1000 PD) was empiric therapy for suspected infection. Sixty-three percent (216.2 DOT/1000 PD) was discontinued at approximately 48 hours when cultures were sterile (68% >48 hours, 32% ≤48 hours). Twenty-six percent of all antibiotic use (89.4 DOT/1000 PD) was therapy for ≥5 days despite sterile cultures; pneumonia (16%) and “culture-negative” sepsis (8%) were the major contributors. Five percent (17.4 DOT/1000 PD) of antibiotic use was for culture-proven sepsis, 5% (16.6 DOT/1000 PD) was penicillin prophylaxis for group B Streptococcus and 1% (3.5 DOT/1000 PD) was preprocedural prophylaxis. Conclusions: Narrow-spectrum therapy accounted for >92% of antibiotic use and would not be monitored by most stewardship programs. Only 5% of antibiotic usage was due to culture-proven infection. Pneumonia and “culture-negative” sepsis were frequent reasons for prolonged therapy; further study of these conditions may allow reduction in treatment duration.
- 1 March 2015
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 34 (3) , 267-272
Prospective Surveillance of Antibiotic Use in the Neonatal Intensive Care Unit
Background: Prolonged or unnecessary antibiotic use is associated with adverse outcomes in neonates. Our objectives were to quantify all antibiotic use in a Level-III neonatal intensive care unit and to identify scenarios where their use could be reduced. Methods: Surveillance and evaluation of all antibiotic use provided to every infant admitted to a Level-III neonatal intensive care unit from 10/3/11 to 11/30/12 was performed. Types of antibiotics, reasons for their initiation, discontinuation and duration, as well as clinical, laboratory and outcome data were recorded. Antibiotic use was quantified by days of therapy (DOT) per 1000 patient-days (PD). Results: A total of 1607 infants were included. The total antibiotic use was 9165 DOT (343.2 DOT/1000 PD; 5.7 DOT/infant). Seventy-two percent of infants received 1 (43%) or more (29%) courses of antibiotics. Gentamicin (46%), ampicillin (39%) and oxacillin (8%) were the most frequently used agents. Ninety-four percent of antibiotic use (323 DOT/1000 PD) was empiric therapy for suspected infection. Sixty-three percent (216.2 DOT/1000 PD) was discontinued at approximately 48 hours when cultures were sterile (68% >48 hours, 32% ≤48 hours). Twenty-six percent of all antibiotic use (89.4 DOT/1000 PD) was therapy for ≥5 days despite sterile cultures; pneumonia (16%) and “culture-negative” sepsis (8%) were the major contributors. Five percent (17.4 DOT/1000 PD) of antibiotic use was for culture-proven sepsis, 5% (16.6 DOT/1000 PD) was penicillin prophylaxis for group B Streptococcus and 1% (3.5 DOT/1000 PD) was preprocedural prophylaxis. Conclusions: Narrow-spectrum therapy accounted for >92% of antibiotic use and would not be monitored by most stewardship programs. Only 5% of antibiotic usage was due to culture-proven infection. Pneumonia and “culture-negative” sepsis were frequent reasons for prolonged therapy; further study of these conditions may allow reduction in treatment duration.
- 1 June 2014
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 28 (2) , 247-261
Antimicrobial Stewardship in the NICU
- 1 June 2014
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 28 (2) , 247-261
Antimicrobial Stewardship in the NICU
- 1 June 2014
- Published by Elsevier in The Journal of Pediatrics
- Vol. 164 (6) , 1489-1492.e1
Pertussis: A Persistent Cause of Morbidity and Mortality in Young Infants
- 1 June 2014
- Published by Elsevier in The Journal of Pediatrics
- Vol. 164 (6) , 1489-1492.e1
Pertussis: A Persistent Cause of Morbidity and Mortality in Young Infants
- 25 January 2014
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 10 (1) , 24-28
Late and very late onset group B Streptococcus sepsis: one and the same?
Background This study aimed to describe the clinical characteristics of group B Streptococcus (GBS) sepsis in infants aged 4–90 days [late onset (LO)] compared to infants >90 days of age [very late onset (VLO)]. Methods Microbiology records at Children’s Medical Center Dallas were screened. Demographic, clinical, and outcome data were collected for infants with GBS recovered from blood or cerebrospinal fluid culture from January 1, 2006 to July 1, 2012. Results Totally 48 infants were identified (42 LO, 6 VLO). Infants with VLO sepsis had lower median gestational age (28.5 vs. 39 weeks gestation, Pvs. 0.5 weeks, P=0.004). When gestational age was controlled for, there were no differences in clinical presentation, intensive care unit admission, length of stay, neurodevelopmental outcome, and mortality. Infants with VLO sepsis were more likely to receive vancomycin (83% vs. 33%, P=0.02) or third-generation cephalosporins (83% vs. 24%, P=0.009), and more likely to continue on those agents even after GBS was identified. Conclusions Infants with VLO sepsis had lower gestational ages and longer nursery stays than infants with LO sepsis. Beyond age at presentation, there were no significant differences in clinical presentations, hospital course, frequency of neurodevelopmental sequelae, and mortality in infants presenting with LO vs. VLO GBS sepsis. Infants with VLO sepsis were more likely to receive empiric broad spectrum antimicrobials and more likely to continue receiving broad therapy even following GBS identification.
- 25 January 2014
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 10 (1) , 24-28
Late and very late onset group B Streptococcus sepsis: one and the same?
Background This study aimed to describe the clinical characteristics of group B Streptococcus (GBS) sepsis in infants aged 4–90 days [late onset (LO)] compared to infants >90 days of age [very late onset (VLO)]. Methods Microbiology records at Children’s Medical Center Dallas were screened. Demographic, clinical, and outcome data were collected for infants with GBS recovered from blood or cerebrospinal fluid culture from January 1, 2006 to July 1, 2012. Results Totally 48 infants were identified (42 LO, 6 VLO). Infants with VLO sepsis had lower median gestational age (28.5 vs. 39 weeks gestation, Pvs. 0.5 weeks, P=0.004). When gestational age was controlled for, there were no differences in clinical presentation, intensive care unit admission, length of stay, neurodevelopmental outcome, and mortality. Infants with VLO sepsis were more likely to receive vancomycin (83% vs. 33%, P=0.02) or third-generation cephalosporins (83% vs. 24%, P=0.009), and more likely to continue on those agents even after GBS was identified. Conclusions Infants with VLO sepsis had lower gestational ages and longer nursery stays than infants with LO sepsis. Beyond age at presentation, there were no significant differences in clinical presentations, hospital course, frequency of neurodevelopmental sequelae, and mortality in infants presenting with LO vs. VLO GBS sepsis. Infants with VLO sepsis were more likely to receive empiric broad spectrum antimicrobials and more likely to continue receiving broad therapy even following GBS identification.
- 1 November 2013
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 32 (11) , 1205-1207
Neonatal Herpes Simplex Virus Infections
- 1 November 2013
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 32 (11) , 1205-1207
Neonatal Herpes Simplex Virus Infections